Compare DCTH & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCTH | SENS |
|---|---|---|
| Founded | 1988 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.4M | 476.9M |
| IPO Year | 2015 | 2014 |
| Metric | DCTH | SENS |
|---|---|---|
| Price | $14.42 | $7.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $24.00 | $13.67 |
| AVG Volume (30 Days) | 251.9K | ★ 559.3K |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.53 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | $24.61 | $82.21 |
| Revenue Next Year | $24.27 | $55.63 |
| P/E Ratio | $368.38 | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $8.12 | $4.79 |
| 52 Week High | $17.42 | $10.64 |
| Indicator | DCTH | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 39.08 | 34.74 |
| Support Level | $14.26 | $7.35 |
| Resistance Level | $16.51 | $7.57 |
| Average True Range (ATR) | 0.51 | 0.48 |
| MACD | -0.06 | -0.21 |
| Stochastic Oscillator | 17.28 | 8.79 |
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.